Multiple Ascending Dose Phase I Study in Order to Define Lanifibranor (IVA337) Supra-thjerapeutic Dose
Status:
Completed
Trial end date:
2019-08-27
Target enrollment:
Participant gender:
Summary
The study will be a double-blind, randomized, placebo-controlled, multiple ascending dose
study with lanifibranor. The study will consist of up to 3 cohorts of 12 subjects each;
therefore, approximately 36 subjects will be included in this study.